{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:42:59Z","timestamp":1793727779155,"version":"4.6.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["US201662309793P"],"award-info":[{"award-number":["US201662309793P"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cmi.2026.05.036","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:01:58Z","timestamp":1780329718000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Population pharmacokinetics of polymyxin B: an individual participant data meta-analysis"],"prefix":"10.1016","author":[{"given":"Saikumar","family":"Matcha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauri G.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick O.","family":"Hanafin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqiang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre P.","family":"Zavascki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Sandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc H.","family":"Scheetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine J.","family":"Kubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayesh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin P.Z.","family":"Cherng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Calfee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Bolon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony W.","family":"Purcell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger L.","family":"Nation","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Pogue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith S.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.05.036_bib1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.05.036_bib2","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990\u20132021: A systematic analysis with forecasts to 2050","volume":"404","author":"Naghavi","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.05.036_bib3","unstructured":"World Health Organization. WHO publishes list of bacteria for which new antibiotics are urgently needed. Geneva: World Health Organization; 2017. Available from: https:\/\/www.who.int\/news\/item\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed"},{"key":"10.1016\/j.cmi.2026.05.036_bib4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1473-3099(14)70850-3","article-title":"Framework for optimisation of the clinical use of colistin and polymyxin B: The Prato polymyxin consensus","volume":"15","author":"Nation","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.05.036_bib5","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3390\/antibiotics12111597","article-title":"A review of resistance to polymyxins and evolving mobile colistin resistance gene (MCR) among pathogens of clinical significance","volume":"12","author":"Shahzad","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.cmi.2026.05.036_bib6","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1124\/pharmrev.120.000020","article-title":"Rescuing the last-line polymyxins: Achievements and challenges","volume":"73","author":"Nang","year":"2021","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.cmi.2026.05.036_bib7","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00483-18","article-title":"Personalizing polymyxin B dosing using an adaptive feedback control algorithm","volume":"62","author":"Lakota","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.05.036_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2026.05.036_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02319-16","article-title":"Nephrotoxicity of polymyxins: Is there any difference between colistimethate and polymyxin B?","volume":"61","author":"Zavascki","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.05.036_bib10","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/cid\/cit334","article-title":"Population pharmacokinetics of intravenous polymyxin B in critically ill patients: Implications for selection of dosage regimens","volume":"57","author":"Sandri","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.05.036_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01475-17","article-title":"Population pharmacokinetics of polymyxin B in acutely ill adult patients","volume":"62","author":"Miglis","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.05.036_bib12","article-title":"Population pharmacokinetics of polymyxin B in obese patients for resistant Gram-negative infections","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cmi.2026.05.036_bib13","doi-asserted-by":"crossref","first-page":"e01900","DOI":"10.1128\/AAC.01900-20","article-title":"Comparing the population pharmacokinetics of and acute kidney injury due to polymyxin B in Chinese patients with or without renal insufficiency","volume":"65","author":"Wang","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.05.036_bib14","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.cmi.2023.05.018","article-title":"A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patients","volume":"29","author":"Hanafin","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.05.036_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00792-21","article-title":"Pharmacokinetics of polymyxin B in hospitalized adults with cystic fibrosis","volume":"65","author":"Crass","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.05.036_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106693","article-title":"Pharmacokinetics and pharmacodynamics of polymyxin B and proposed dosing regimens in elderly patients with multi-drug-resistant gram-negative bacterial infections","volume":"60","author":"Wang","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2026.05.036_bib17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00228-022-03415-x","article-title":"Comparative polymyxin B pharmacokinetics in critically ill patients with renal insufficiency and in continuous veno-venous hemodialysis","volume":"79","author":"Surovoy","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cmi.2026.05.036_bib18","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/phar.2129","article-title":"Polymyxin B pharmacokinetics in adult cystic fibrosis patients","volume":"38","author":"Avedissian","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2026.05.036_bib19","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3389\/fphar.2020.00829","article-title":"Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of polymyxin B in Chinese patients with multidrug-resistant gram-negative bacterial infections","volume":"11","author":"Wang","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cmi.2026.05.036_bib20","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1111\/bcp.14576","article-title":"Population pharmacokinetic and optimization of polymyxin B dosing in adult patients with various renal functions","volume":"87","author":"Yu","year":"2021","journal-title":"Brit J Clinical Pharma"},{"key":"10.1016\/j.cmi.2026.05.036_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1019411","article-title":"Population pharmacokinetic analysis, renal safety, and dosing optimization of polymyxin B in lung transplant recipients with pneumonia: A prospective study","volume":"13","author":"Cai","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cmi.2026.05.036_bib22","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1111\/jcpt.13711","article-title":"The population pharmacokinetics and dose optimization of polymyxin B in critically ill patients with or without extracorporeal membrane oxygenation","volume":"47","author":"Ye","year":"2022","journal-title":"J Clin Pharm Ther."},{"key":"10.1016\/j.cmi.2026.05.036_bib23","article-title":"Population pharmacokinetics of polymyxin B and dosage optimization in renal transplant patients","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cmi.2026.05.036_bib24","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00228-024-03666-w","article-title":"Pharmacokinetics of polymyxin B in different populations: A systematic review","volume":"80","author":"Wang","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cmi.2026.05.036_bib25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.21037\/atm-22-236","article-title":"Population pharmacokinetics of polymyxin B: A systematic review","volume":"10","author":"Chen","year":"2022","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.cmi.2026.05.036_bib26","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/psp4.13002","article-title":"Pharmacokinetic analysis across studies to drive knowledge-integration: A tutorial on individual patient data meta-analysis (IPDMA)","volume":"12","author":"Van Wijk","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.cmi.2026.05.036_bib27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jinf.2021.01.006","article-title":"Acute toxicity is a dose-limiting factor for intravenous polymyxin B: A safety and pharmacokinetic study in healthy Chinese subjects","volume":"82","author":"Liu","year":"2021","journal-title":"J Infect"},{"key":"10.1016\/j.cmi.2026.05.036_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.975066","article-title":"Pharmacokinetics\/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae","volume":"13","author":"Yu","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cmi.2026.05.036_bib29","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/cpt.3729","article-title":"Population pharmacokinetic\/toxicodynamic model for polymyxin B in critically ill patients to identify the risk of nephrotoxicity","volume":"118","author":"Hanafin","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cmi.2026.05.036_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106214","article-title":"Population pharmacokinetics of polymyxin B and dosage strategy in critically ill patients with\/without continuous renal replacement therapy","volume":"175","author":"Luo","year":"2022","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.cmi.2026.05.036_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115291","article-title":"Determination of polymyxin B in human plasma and epithelial lining fluid using LC-MS\/MS and its clinical application in therapeutic drug monitoring","volume":"227","author":"Zhang","year":"2023","journal-title":"J Pharm Biomed Anal."},{"key":"10.1016\/j.cmi.2026.05.036_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1122310","article-title":"Population pharmacokinetic analysis and dosing optimization of polymyxin B in critically ill patients","volume":"14","author":"Liang","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cmi.2026.05.036_bib33","first-page":"F151","article-title":"Hydrolysis and transport of small peptides by the proximal tubule","volume":"238","author":"Carone","year":"1980","journal-title":"Am J Physiol"},{"key":"10.1016\/j.cmi.2026.05.036_bib34","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1021\/acs.chemrestox.5b00262","article-title":"Investigating nephrotoxicity of polymyxin derivatives by mapping renal distribution using mass spectrometry imaging","volume":"28","author":"Nilsson","year":"2015","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.cmi.2026.05.036_bib35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.saa.2019.03.077","article-title":"Polymyxins interaction to the human serum albumin: A thermodynamic and computational study","volume":"217","author":"Poursoleiman","year":"2019","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"10.1016\/j.cmi.2026.05.036_bib36","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.bcp.2012.05.004","article-title":"Structure\u2013activity relationships for the binding of polymyxins with human \u03b1-1-acid glycoprotein","volume":"84","author":"Azad","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.cmi.2026.05.036_bib37","first-page":"3291","article-title":"New pharmacokinetic\/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: Smaller response in lung infection","volume":"70","author":"Cheah","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.05.036_bib38","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1002\/psp4.13040","article-title":"Mid-dosing interval concentration is important for polymyxin B exposure and acute kidney injury in critically ill patients","volume":"12","author":"Wang","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.cmi.2026.05.036_bib39","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s13054-023-04522-6","article-title":"Polymyxin B therapy based on therapeutic drug monitoring in carbapenem-resistant organisms sepsis: The PMB-CROS randomized clinical trial","volume":"27","author":"Liu","year":"2023","journal-title":"Crit Care"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26002788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26002788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:48:29Z","timestamp":1787024909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X26002788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":39,"alternative-id":["S1198743X26002788"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.05.036","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetics of polymyxin B: an individual participant data meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.05.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}